Comparison of Immunomodulative Effects of the Histamine-2 Receptor Antagonists Cimetidine, Ranitidine, and Famotidine on Peripheral Blood Mononuclear Cells in Gastric Cancer Patients

References

• Beer D J, Rocklin R E. Histamine-induced suppressor cell activity. J Allergy Clin Immunol 1984; 73: 439–52
   PubMedGoogle Scholar
• Bartholyns J, Fozard J R. Role of histamine in tumor development. Trends Pharmacol Sci 1985; 6: 123–5
   Google Scholar
• Rocklin R E. Modulation of cellular-immune response in vivo and in vitro by histamine receptor-bearing lymphocytes. J Clin Invest 1976; 57: 1051–8
   PubMed Web of Science ®Google Scholar
• Wang S R, Zweiman B. Histamine suppression of human lymphocyte response to mitogens. Cell Immunol 1978; 36: 28–36
   PubMedGoogle Scholar
• Gifford R RM, Hatfield S M, Schmidtke J R. Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen, bacterial antigen, and alloantigen. Transplantation 1980; 29: 143–8
   PubMed Web of Science ®Google Scholar
• Gifford R RM, Tilberg A F. Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production. Surgery 1987; 102: 242–7
   PubMed Web of Science ®Google Scholar
• Gifford R RM, Voss B V, Schmidtke J R, Ferguson R M. Histamine type-2 receptor antagonist immune modulation. I. Increased cell-mediated cytotoxicity in normal and in down-regulated systems. Surgery 1988; 103: 184–92
   PubMed Web of Science ®Google Scholar
• Rocklin R E. Histamine-induced suppressor factor (HSF): effect on migration inhibitory factor (MIF) production and proliferation. J Immunol 1977; 118: 1734–8
   PubMed Web of Science ®Google Scholar
• Rocklin R E, Breard J, Gupta S, Good R A, Melmon K L. Characterization of the human blood lymphocytes that produce a histamine-induced suppressor factor (HSF). Cell Immunol 1980; 51: 226–37
   PubMed Web of Science ®Google Scholar
• Simon M R, Salberg D J, Crane S A. In vivo cimetidine augmentation of phytohemmagglutinin-induced human lymphocyte thymidine uptake. Transplantation 1981; 31: 400–1
   PubMedGoogle Scholar
• Sansoni P, Silverman E D, Khan M M, Melmon K L, Engleman E G. Immunoregulatory T cells in man. Histamine induced suppressor cells are derived from a Leu-2+ subpopulation distinct from that which gives rise to cytotoxic T cell. J Clin Invest 1985; 75: 650–6
   PubMedGoogle Scholar
• Armitage J O, Sidner R D. Antitumor effect of cimetidine?. Lancet 1979; 1: 882–3
   PubMedGoogle Scholar
• Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistamines (ranitidine or cimetidine). Eur J Cancer Clin Oncol 1988; 24: 161–7
   PubMedGoogle Scholar
• Thornes R D, Lynch E, Sheehan M V. Cimetidine and coumarin therapy of melanoma. Lancet 1982; 2: 328
   PubMed Web of Science ®Google Scholar
• Mamus S W, Mladenovic J, Hordinsky M K, Dahl M V, Kay N E. Cimetidine-induced remission of mycoides fungoides. Lancet 1984; 2: 409
   PubMed Web of Science ®Google Scholar
• Tonnesen H, Knigge U, Bulow S, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988; 2: 990–1
   PubMed Web of Science ®Google Scholar
• Vecchia C L, Negri E, D'Avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet 1990; 336: 355–7
   PubMedGoogle Scholar
• Tsunoda T, Tanimura H, Yamaue H, et al. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmacol 1992; 14: 75–81
   PubMedGoogle Scholar
• Peden N R, Robertson A J, Boyd E JS, et al. Mitogen stimulaticn of peripheral blood lymphocytes of duodenal ulcer patients during treatment with cimetidine or ranitidine. Gut 1982; 23: 398–403
   PubMed Web of Science ®Google Scholar
• Texter E C, Miyoshi A, Okabe H. Famotidine: further development in H2-receptor antagonists therapy. Scand J Gastroenterol 1987; 22: 1–62
   PubMed Web of Science ®Google Scholar
• Calvieri S, Fattorossi A. Cimetidine for Kaposi's sarcoma. Clin Exp Dermatol 1985; 10: 499–501
   PubMedGoogle Scholar
• Smith T. Histamine type 2-receptor antagonists and cancer immunotherapy. Compr Ther 1990; 16: 8–13
   PubMedGoogle Scholar
• Nielsen H J, Hammer J H, Moesgaard F, Kehlet H. Possible role of histamine type-2 receptor antagonists for adjuvant treatment in colorectal cancer. Eur J Surg 1991; 157: 437–41
   PubMedGoogle Scholar
• Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19: 29–44
   PubMed Web of Science ®Google Scholar
• Feldman M, Burton M E. Histamine2-receptor antagonists—standard therapy for acid-peptic diseases. N Engl J Med 1990; 323: 1672–80
   PubMedGoogle Scholar
• Viciorino R MMM, Hodgson H JF. Relationship between T cell subpopulations and mitogen responsiveness and suppressor cell function of peripheral blood mononuclear cells in normal individuals. Clin Exp Immunol 1980; 42: 571–8
   PubMedGoogle Scholar
• Plaut M, Lichtenstein L M, Henney L S. Properties of a sub-population of T cells bearing histamine receptors. J Clin Invest 1977; 55: 856–74
   Google Scholar
• Beer D J, Rocklin R E. Histamine modulation of lymphocyte biology: membrane receptors, signal transduction, and functions. CRC Crit Rev Immunol 1987; 7: 55–91
   Google Scholar
• Garovoy M R, Reddish M A, Rocklin R E. Histamine-induced suppressor factor (HSF): inhibition of helper T cell generation and function. J Immunol 1983; 130: 357–61
   PubMed Web of Science ®Google Scholar
• Nanda N, Nath N. Characteristics of histamine receptors present on suppressor T cells in ‘healthy individuals’. Int J Immunopharmacol 1985; 7: 587–95
   PubMedGoogle Scholar
• Cameron W, Doyle K, Rocklin R E. Histamine type-1 receptor radioligand binding studies on normal T cell subsets, B cells, and monocytes. J Immunol 1986; 136: 2116–20
   PubMedGoogle Scholar
• Griswold D E, Alessi S, Badger A M, Poste G, Hanna N. Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol 1984; 132: 3054–7
   PubMed Web of Science ®Google Scholar
• Rubin L A, Kurman C C, Fritz M E, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172–7
   PubMed Web of Science ®Google Scholar
• Kikuchi V, Oomon K, Kizaua I, Kato K. Augmented natural killer activity in ovarian cancer patients treated with cimetidine. Eur J Cancer Clin Oncol 1986; 22: 1037–43
   PubMedGoogle Scholar
• Hellstrand K, Hermodsson S. Differential effects of histamine receptor antagonists on human natural killer cell activity. Int Arch Allergy Appl Immunol 1987; 84: 247–55
   PubMedGoogle Scholar
• Korosu Y, Tanaka N, Furusho Y, Morita K. Cimetidine-mediated augmentation of lymphocyte responses to phytohemmagglutinin in gastric cancer patients. Jpn J Clin Oncol 1989; 19: 56–61
   PubMedGoogle Scholar
• Roth J A. Tumor induced immunosuppression. Surg Gynecol Obstet 1983; 156: 233–40
   PubMedGoogle Scholar
• Smith M D, Couhig E, Miller J J. Cimetidine and the immune response. Lancet 1979; 1: 1406
   PubMedGoogle Scholar
• Roenn J V, Harris J E, Braun D P. Suppressor cell function in solid tumor cancer patients. J Clin Oncol 1987; 5: 150–9
   PubMedGoogle Scholar
• Burtin C, Scheinmann P, Salomon J C, Lespinats G, Canu P. Decrease in tumor growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer 1982; 45: 54–60
   PubMed Web of Science ®Google Scholar